Last edition
News about "Amgen TEPEZZA Phase 3 results"
Amgen Announces Positive Phase 3 Results for TEPEZZA
Amgen reports positive Phase 3 topline results for subcutaneous TEPEZZA in thyroid eye disease, with key endpoints met and 77 percent of patients achieving significant proptosis reduction.
Amgen TEPEZZA Phase 3 Results | 07/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members